NCT05152017View on ClinicalTrials.gov

The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 16, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 24, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

Flu-M Quadro [inactivated split influenza vaccine] with preservative

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Flu-M Quadro [inactivated split influenza vaccine] without preservative

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Placebo

solution for intramuscular injection, 0.5 ml

Trial Locations (1)

Unknown

Federally Funded Healthcare Institution Primary Healthcare Unit No. 163, Novosibirsk

All Listed Sponsors
lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05152017 - The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers | Biotech Hunter | Biotech Hunter